Telomerase: A tumor antigen for anticancer immunotherapy;La télomérase: Un antigène tumoral universel pour l'immunothérapie anti-cancéreuse

Medecine/Sciences

Volumn 20, Issue 1, 2004, Pages 19-21

  Adotévi, Olivier ^a,b   Garcia Pons, Francisco ^a   Langlade Demoyen, Pierre ^a  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; IMMUNOLOGIC AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE DERIVATIVE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; IMMUNIZATION; IN VIVO STUDY; NOTE; T LYMPHOCYTE; TELOMERE; TUMOR IMMUNITY; VACCINATION;

EID: 18244413430     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200420119     Document Type: Note

References (19)

1. Pardoll D. T cells and tumors. Nature 2001; 411: 1010-2.
2. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-4.
3. Blackburn EH. Telomerases. Annu Rev Biochem 1992; 61: 113-29.
4. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal celles which express telomerase activity. EMBO J 1992; 11: 1921-9.
5. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal celles an cancer. Science 1994; 266: 2011-5.
6. Broccoli D, Young JW, de Lange T. Telomerase activity in normal an malignant hematopoietic cells. Proc Natl Acad Sci USA 1995; 92: 9082-6.
7. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor celles an during immortalization. Cell 1997; 90: 785-95.
8. Kim NN. Clinical implications of telomerase in cancer. Eur J Cancer 1997; 33: 781-6.
9. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast an human. Science 1997; 277: 955-9.
10. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell 2002; 2: 257-65.
11. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10: 673-9.
12. Minev B, Hipp J, Firat H, et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000; 97: 4796-801.
13. Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 2001; 7: 3343-8.
14. Vonderheide RH, Schultze JL, Anderson KS, et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001; 61: 8366-70.
15. Nair SK, Heiser A, Boczkowski D, et al. Induction of cytotoxic T cell responses an tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6: 1011-7.
16. Nanda NK, Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell 1995 14; 82: 13-7.
17. Houghton AN. Cancer antigens: immune recognition of self an altered self. J Exp Med 1994; 180: 1-4.
18. Vonderheide RH. Telomerase as a universel tumor-associated antigen for cancer immunotherapy. Oncogene 2002; 21: 674-9.
19. Hernandez J, Garcia-Pons F, Lone YC, et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor celles. Proc Natl Acad Sci USA 2002; 99: 12275-80.